Mahamaya board to meet on May 25 to consider FY26 results
Mahamaya Lifesciences Limited will hold a board meeting on May 25, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until 48 hours post-results declaration.

*this image is generated using AI for illustrative purposes only.
Mahamaya Lifesciences Limited has announced that its board of directors will meet on Monday, May 25, 2026. The primary agenda of the meeting is to consider and approve the company's financial performance for the fiscal year ending March 31, 2026.
Agenda for the Meeting
The board will deliberate on the audited standalone financial results for the half year and financial year ended March 31, 2026, along with the accompanying audit report. Additionally, the directors will consider the audited consolidated financial results for the same periods.
Trading Window Closure
In continuation of a previous intimation dated March 30, 2026, regarding the closure of the trading window, the company stated that the window will remain shut. The closure is effective until 48 hours after the declaration of the financial results, in accordance with the company's Insider Trading Code and the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The meeting is scheduled to be held at the company's registered office located in Gurugram, Haryana.
Historical Stock Returns for Mahamaya Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.58% | -2.20% | -0.46% | +48.05% | +49.14% | +49.14% |
How might Mahamaya Lifesciences' FY2026 financial results compare to industry peers in the life sciences sector, and what growth trajectory could investors expect going forward?
Following the board meeting on May 25, 2026, will the company announce any dividend declarations, capital expenditure plans, or strategic expansions that could impact its stock performance?
How could the reopening of the trading window after the results announcement influence institutional and retail investor sentiment toward Mahamaya Lifesciences stock?

































